Deutz F J, Rübben H, Küpper W, Hofstädter F
Department of Urology, Medical Faculty, University of Aachen, Federal Republic of Germany.
Urol Res. 1989;17(4):223-7. doi: 10.1007/BF00262597.
To analyze the effect of chemical carcinogens on urothelial and intestinal mucosa on 214 female Wistar rats an ureterosigmoidostomy was performed. After 10-14 days 123 surviving rats were randomly divided into 4 groups: Group I-III received 0.05 per cent N-Butyl-N-(4-hydroxybutyl)-nitrosamine (BBN) in drinking water over a period of 15 weeks. Group IV received normal drinking water over the same period. The defunctionalized bladders were instilled each second day: Group I: physiologic saline solution, Group II: urine of normal rats, Group III and IV: urine of BBN-treated rats. 30 rats without diversion but BBN treatment served as a control. The evaluation of the histological data gave the following results: In the control group urothelial tumors were found in the bladder exclusively. Dependent on the grade of obstruction in the BBN-treated groups, with diversion urothelial tumors in the renal pelvis and ureter could be documented, whereas in the bladder no tumor growth could be shown. In the intestinal mucosa of BBN-treated animals a high incidence of adenocarcinoma was found. The chemical tumor induction by BBN is related to the urine and takes place by direct contact to the mucosa when the metabolites excreted by the kidneys are activated in the urine. BBN or other urogenic carcinogens seem to have no urothelial specificity. The incidence of bowel carcinoma after diversion must lead to intensive long-term follow up.
为分析化学致癌物对214只雌性Wistar大鼠输尿管乙状结肠吻合术后膀胱和肠道黏膜的影响,在术后10 - 14天,将123只存活大鼠随机分为4组:第I - III组在15周内饮用含0.05% N - 丁基 - N -(4 - 羟丁基)亚硝胺(BBN)的饮用水,第IV组同期饮用正常饮用水。每隔一天向去功能化膀胱内灌注:第I组:生理盐水溶液;第II组:正常大鼠尿液;第III组和第IV组:经BBN处理大鼠的尿液。30只未行改道但接受BBN处理的大鼠作为对照。组织学数据评估结果如下:对照组仅在膀胱发现尿路上皮肿瘤。在经BBN处理的组中,根据梗阻程度,改道组可记录到肾盂和输尿管的尿路上皮肿瘤,而膀胱未显示肿瘤生长。在经BBN处理动物的肠道黏膜中发现腺癌的高发病率。BBN诱导化学性肿瘤与尿液有关,当肾脏排泄的代谢产物在尿液中被激活时通过与黏膜直接接触发生。BBN或其他泌尿生殖系统致癌物似乎没有尿路上皮特异性。改道后肠癌的发病率必须进行长期密切随访。